Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Headache Attributed to TMD
NCT03346252Phase 1Completed
- Sponsor
- University at Buffalo
- Start
- May 2017
- Primary completion
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of botulinum toxin type A in Headache attributed to temporomandibular disorder, sponsored by University at Buffalo. Primary endpoints: Headache Frequency at 48 weeks, Headache Impact Test-6 at 48 weeks and 1 more. Started May 2017; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Headache attributed to temporomandibular disorder
Beyond the preview
Go deeper on NCT03346252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03346252.